New NDSS subsidy update
Wednesday, 1 June 2022
Have you heard the exciting news?
From 1 July 2022, ALL Australians living with type 1 diabetes will be eligible for subsidised access to FreeStyle Libre 2 through the NDSS.
This announcement was recently made by the Federal Government and received bipartisan support from both major parties, which means that in the new expanded scheme, all Australians living with Type 1 diabetes will get access to subsidised FreeStyle Libre 2 from 1 July 2022.
Abbott is grateful to the diabetes community for your continued support, and look forward to supporting your transition onto subsidised FreeStyle Libre 2 over the next few weeks!
What do I need to do now?
The current process for receiving subsidised access to FreeStyle Libre 2 requires an authorised healthcare professional to complete and submit an NDSS eligibility form on your behalf.
Assuming this eligibility form process remains the same, we encourage you to contact your healthcare professional now to secure an appointment from 1st July onwards – in order to have your subsidised FreeStyle Libre 2 access approved in a timely manner. Securing an appointment after 1 July now may help minimise delays in being approved for subsidised FreeStyle Libre 2.
MORE ABOUT FREESTYLE LIBRE 2
FreeStyle Libre 2 is a real time CGM (Continuous Glucose Monitor) with optional alarms and zero finger pricks!† Know where your glucose level is and where it is heading with a quick scan of the FreeStyle LibreLink app1 over the small and discreet sensor. It provides unsurpassed 14-day accuracy2, even when you are in the low glucose range.
You can also share real-time glucose data and alarms with your healthcare professional, friends and family all through the FreeStyle LibreLink app1
The FreeStyle Libre system is the #1 sensor-based glucose monitoring system used worldwide††.
FreeStyle Libre 2 is intended for use by adults and children (4 years and older) with insulin requiring diabetes.
†Finger pricks are required if your glucose readings and alarms do not match symptoms or expectations.
††Data based on the number of users worldwide for the FreeStyle Libre system and compared to the number of users for other leading personal use sensor-based glucose monitoring systems.
1.The FreeStyle LibreLink app is only compatible with certain mobile devices and operating systems. For more information about device compatibility for the FreeStyle LibreLink app, click here. Use of FreeStyle LibreLink requires registration with LibreView. 2. Alva et al. Accuracy of a 14-Day Factory-Calibrated Continuous Glucose Monitoring System With Advanced Algorithm in Pediatric and Adult Population With Diabetes. Journal of Diabetes Science and Technology 1–8 DOI: 10.1177/1932296820958754.
FreeStyle, Libre, and related brand marks are marks of Abbott. Information contained herein is for distribution outside of the USA only. Abbott Australasia Pty. Ltd., Abbott Diabetes Care, 666 Doncaster Road, Doncaster, Victoria 3108, Australia. ABN 95 000 180 389. ADC-58319 v1.0